BlackRock’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

BlackRock’s Portfolio EUCRW Stock Details EUCRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-251,162	Closed	-$6K	–	5884
2022 Q3	$6K	Sell	251,162 -46,843	-16%	-$2.96K	﹤0.01%	5628
2022 Q2	$9K	Sell	298,005 -2,039	-0.7%	-$328	﹤0.01%	5643
2022 Q1	$56K	Hold	300,044	–	–	﹤0.01%	5403
2021 Q4	$173K	Sell	300,044 -8,289	-3%	-$6.1K	﹤0.01%	5138
2021 Q3	$221K	Hold	308,333	–	–	﹤0.01%	4962
2021 Q2	$321K	Buy	308,333 +2	+0%	+$2	﹤0.01%	4793
2021 Q1	$386K	Buy	+308,331	New	+$500K	﹤0.01%	4647

Other funds holding EUCRW

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

ACM

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

BlackRock's EUCRW Position: Q4 2022 in Review

BlackRock sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q4 2022, closing a stake of 251,162 shares — an estimated $6K sold.

BlackRock first reported a position in EUCRW in Q1 2021 and held it in 7 quarters. The position peaked at $386K in Q1 2021. 25 funds tracked by Wall St. Rank hold EUCRW as of Q4 2022.

BlackRock reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q4 2022 after selling out during the quarter.
BlackRock sold 251,162 Eucrates Biomedical Acquisition Corp. Warrant shares in Q4 2022, an estimated $6K.
BlackRock first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q1 2021 and held it in 7 quarters.
BlackRock's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $386K in Q1 2021.
25 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q4 2022.

Based on BlackRock's 13F filing for Q4 2022, filed 13 Feb 2023.